Paper Review Records
All Paper Review Records
20 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
33
days
Sleep duration links to biological aging clocks: when sleep gets tough, aging gets going
Authors
Despina Tawadros; Melek Canan ArkanShow moreShow less
Affiliations
1. Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt/Main, Germany; 2. Frankfurt Cancer Institute, Goethe University Frankfurt, Frankfurt/Main, Germany; 3. German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, GermanyShow moreShow less
101
days
Dynamics of neutralizing antibody responses after trivalent XBB.1.5 booster vaccination: a 480-day longitudinal study
Authors
Meng-Fei Wang; Guo-Ping Cao; Guo-Jian Yang; Xue-Dong Song; Bing-Dong Zhan; Mai-Juan MaShow moreShow less
Affiliations
1. The First Hospital of Hebei Medical University, Hebei Medical University, Shijiazhuang, China; 2. State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China; 3. Department of Infectious Disease Control and Prevention, Quzhou Center for Disease Control and Prevention, Quzhou, China; 4. Department of Infectious Disease Control and Prevention, Jinan Center for Disease Control and Prevention, Jinan, China; 5. Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Shijiazhuang, China; 6. Department of Laboratory Medicine, Handan Central Hospital, Hebei Medical University, Handan, ChinaShow moreShow less
306
days
Nucleic acid aptamers: new methods for selection, target validation, molecular diagnostics and therapeutics
Authors
Ding-Kun Ji; Haozhi Lei; Jia Liu; Fangfang Xia; Xiaobo Gao; Yi-Qing Zhou; Ruiying Li; Yongqi Han; Ruowen Wang; Weihong TanShow moreShow less
Affiliations
1. Institute of Molecular Medicine (IMM), Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; 2. Medical and Engineering Cross Research Institute, The First Affiliated Hospital of Henan University, Henan University, Kaifeng, China; 3. Department of Anatomy and Physiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 4. Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), The Chinese Academy of Sciences, Hangzhou, ChinaShow moreShow less
41
days
EBV-driven Gate–License–Amplify circuit in multiple sclerosis pathogenesis
Authors
Yuxin Li; Xiaofei Shi; Yuxiao Zhang; Mu-Sheng Zeng; Qian Zhong; Wanli LiuShow moreShow less
Affiliations
1. School of Management & Engineering, Nanjing University, Nanjing, China; 2. Jiangsu Key Laboratory of Digital Finance, Suzhou, China; 3. State Key Laboratory of Membrane Biology, School of Life Sciences, Tsinghua-Peking Center for Life Sciences, Institute for Immunology, Ministry of Education Key Laboratory of Protein Sciences, Tsinghua University, Beijing, China; 4. Department of Rheumatology and Immunology, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, China; 5. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, ChinaShow moreShow less
257
days
Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial
Authors
Linong Ji; Leili Gao; Ben Li; Mei Liu; Xianghua Zhang; Chao MengShow moreShow less
Affiliations
1. Department of Endocrinology, Peking University People’s Hospital, Beijing, China; 2. Chengdu Vincentage Pharma Co. Ltd., Chengdu, China; 3. Department of General Medicine, Yueyang Central Hospital, Yueyang, China; 4. Department of General Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, ChinaShow moreShow less
302
days
Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study
Authors
Jia Yu; Anwen Xiong; Qiming Wang; Jianhua Chen; Hongrui Niu; Chengzhi Zhou; Panwen Tian; Wu Zhuang; Jie Li; Jing Wang; Junguo Lu; Kangsheng Gu; Jinsheng Shi; Jun Guo; Yonghui Di; Dongqing Lv; Debin Sun; Liming Cao; Zhixiong Yang; Jingxun Wu; Liyun Miao; Yueyin Pan; Chong Li; Xiaohong Wu; Jie Yin; Xiang Wang; Meili Sun; Miao He; Shundong Cang; Haohui Fang; Ping Chen; Min Zhang; Xinmei Yang; Hui Zhao; Jian Feng; Xuezhen Ma; Sheng Hu; Jian Lu; Xin Zhao; Zhixiang Zhuang; Yilan Sun; Xu Sun; Bing Yu; Chaonan Zhu; Jianghua Chen; June Xu; Kai Wang; Caicun ZhouShow moreShow less
Affiliations
1. Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China; 2. Department of Respiratory Medicine, Henan Cancer Hospital, Zhengzhou, China; 3. Department of Medical Oncology, Hunan Cancer Hospital, Changsha, China; 4. Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China; 5. State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; 6. Department of Respiratory and Critical Care Medicine, West China School of Medicine/West China Hospital of Sichuan University, Chengdu, China; 7. Department of Thoracic Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, China; 8. Department of Respiratory Medicine, First Affiliated Hospital of Gannan Medical University, Ganzhou, China; 9. Department of Respiratory Medicine, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 10. Department of Respiratory Medicine, Nantong Tumor Hospital, Nantong, China; 11. Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China; 12. Department of Oncology, Cangzhou People’s Hospital, Cangzhou, China; 13. Department of Medical Oncology, Xingtai People’s Hospital, Hebei, China; 14. Department of Thoracic Surgery, Xingtai People’s Hospital, Xingtai, China; 15. Department of Respiratory Medicine, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, China; 16. Respiratory Department, Lishui Central Hospital, Lishui, China; 17. Department of Respiratory Medicine, Xiangya Hospital Central South University, Changsha, China; 18. Department of Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China; 19. Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China; 20. Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China; 21. Division of Life Sciences and Medicine, Department of Medical Oncology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China; 22. Department of Respiration, First People’s Hospital of Changzhou, Third Affiliated Hospital of Soochow University, Changzhou, China; 23. Department of Medical Oncology, The Affiliated Hospital of Jiangnan University (The Fourth People’s Hospital in Wuxi City), Wuxi, China; 24. Department of Respiratory and Critical Care Medicine, General Hospital of the Eastern Theatre of the Chinese People’s Liberation Army, Nanjing, China; 25. Department of Oncology, Xuzhou Central Hospital, Xuzhou, China; 26. Department of Oncology, Jinan Central Hospital, Jinan, China; 27. Oncology Department, Deyang People’s Hospital, Deyang, China; 28. Department of Oncology, Henan Provincial People’s Hospital, Zhengzhou, China; 29. Department of Respiratory Medicine, Anhui Chest Hospital, Hefei, China; 30. Department of Oncology, Yancheng NO.1 People’s Hospital, Yancheng, China; 31. Department of Pulmonary and Critical Care Medicine, Ganzhou People’s Hospital, Ganzhou, China; 32. Department of Radiation Oncology, The First Hospital of Jiaxing, Jiaxing, China; 33. Department of Respiratory Medicine, Second Affiliated Hospital of Anhui Medical University, Hefei, China; 34. Department of Respiratory and Critical Care Medicine, Affiliated Hospital and Medical School of Nantong University, Nantong, China; 35. Department of Oncology, Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital, Qingdao, China; 36. Department of Thoracic Oncology, Hubei Cancer Hospital, Wuhan, China; 37. Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China; 38. Department of Respiratory and Critical Care Medicine, Jiangsu Province Hospital and The First Affiliated Hospital with Nanjing Medical University, Nanjing, China; 39. Department of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China; 40. Department of Pulmonary and Critical Care Medicine, Zhejiang Provincial People’s Hospital, Hangzhou, China; 41. Hangzhou Zhongmei Huadong Pharmaceutical Company, Hangzhou, China; 42. Department of Respiratory Medicine, The Second Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, China; 43. Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, China; 44. Department of Shanghai East Hospital, Tongji University School of Medicine, Shanghai, ChinaShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days